EGFR tyrosine kinase inhibitor therapy for lung cancer treatments and their clinical outcomes: A cohort study in Taiwan
CH Chung - Oncology Letters, 2019 - spandidos-publications.com
… present retrospective cohort study was … studies comparing gefitinib with erlotinib prescription,
showed that the median PFS in the gefitinib group was higher compared with the erlotinib …
showed that the median PFS in the gefitinib group was higher compared with the erlotinib …
Phase III clinical trial for the combination of erlotinib plus ramucirumab compared with osimertinib in previously untreated advanced or recurrent non–small cell lung …
N Haratake, H Hayashi, M Shimokawa, Y Nakano… - Clinical lung cancer, 2022 - Elsevier
… the FLAURA study revealed that osimertinib did not significantly prolong overall survival (OS)
compared with gefitinib or erlotinib in patients with the L858R. The RELAY study revealed …
compared with gefitinib or erlotinib in patients with the L858R. The RELAY study revealed …
[HTML][HTML] Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations
… received first-generation EGFR TKIs erlotinib or gefitinib as their first EGFR TKI treatment (…
In conclusion, the results of this retrospective real-world cohort study show that patients with …
In conclusion, the results of this retrospective real-world cohort study show that patients with …
[HTML][HTML] EGFR variant allele frequency predicts EGFR-TKI efficacy in lung adenocarcinoma: a multicenter study
B Gieszer, Z Megyesfalvi, V Dulai, J Papay… - … Cancer Research, 2021 - ncbi.nlm.nih.gov
… were included in this multi-center, retrospective study, who … were included who received either
gefitinib or erlotinib as first- or … Another limitation of our study is its retrospective nature with …
gefitinib or erlotinib as first- or … Another limitation of our study is its retrospective nature with …
[HTML][HTML] Does neoadjuvant targeted therapy provide an opportunity for resectable EGFR-mutant lung cancer: a real-world retrospective study
C Lv, Y Ma, Q Feng, F Lu, Y Chi, N Wu… - Journal of Thoracic …, 2020 - ncbi.nlm.nih.gov
… randomized studies have proved that 2 years of adjuvant targeted therapy (gefitinib or
erlotinib) yields longer DFS than conventional adjuvant chemotherapy (20,21). In our study, …
erlotinib) yields longer DFS than conventional adjuvant chemotherapy (20,21). In our study, …
A retrospective look at anti-EGFR agents in pancreatic cancer therapy
HK Verma, PK Kampalli, S Lakkakula… - Current Drug …, 2019 - ingentaconnect.com
… with gefitinib and erlotinib. Advanced pancreatic cancer patients receiving erlotinib monotherapy
… Pancreatic cancer patients treated with EGFR-TKIs gefitinib and erlotinib also showed …
… Pancreatic cancer patients treated with EGFR-TKIs gefitinib and erlotinib also showed …
Efficacy and Prognosis of First-Line EGFR-Tyrosine Kinase Inhibitor Treatment in Older Adults Including Poor Performance Status Patients with EGFR-Mutated Non …
CY Chang, CY Chen, SC Chang, YC Lai… - … and Research, 2021 - Taylor & Francis
… This study was performed as a multicenter, retrospective study of a single medical center …
with poor PS included in the current study were treated with gefitinib or erlotinib. In addition, the …
with poor PS included in the current study were treated with gefitinib or erlotinib. In addition, the …
[HTML][HTML] Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for …
H Yoshioka, M Shimokawa, T Seto, S Morita… - Annals of …, 2019 - Elsevier
… erlotinib as second-line therapy, and one received erlotinib as second-line therapy followed
by gefitinib re-… , although there are some retrospective studies indicating that OS of recurrent …
by gefitinib re-… , although there are some retrospective studies indicating that OS of recurrent …
Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR‐G719A and Other Uncommon EGFR Mutations
… Retrospective clinical studies in patients with advanced NSCLC with uncommon EGFR
mutations have suggested improved progression‐free survival (PFS) on treatment with afatinib …
mutations have suggested improved progression‐free survival (PFS) on treatment with afatinib …
… acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non–small-cell lung cancer: a propensity-matched retrospective study
X Wang, Z Zeng, J Cai, P Xu, P Liang, Y Luo, A Liu - BMC cancer, 2021 - Springer
Background This retrospective study aimed to evaluate the efficacy of epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitors (TKIs) with stereotactic body radiation therapy (…
receptor (EGFR) tyrosine kinase inhibitors (TKIs) with stereotactic body radiation therapy (…